- | Rezolute
Ensuring Patient-Friendly Clinical Trials For Complex Disorders — A Small Biopharma’s Playbook
Rezolute, a small company based in Redwood City, California, and working in the rare pediatric disease space, is developing a new therapeutic option specifically for patients with congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder. For Rezolute, connecting and partnering with advocacy groups and physicians is paramount in clinical trial execution.
- | Amolyt Pharma
First Person Treated in Amolyt Pharma’s AZP-3601 Trial for Hypoparathyroidism
Amolyt Pharma, formerly Alizé Pharma 3, had announced earlier this year its plans to start a clinical trial of AZP-3601 by the end of 2020.
- | Aridis Pharmaceuticals
Inhaled antibody drug for COVID-19 clears coronavirus in animals
Aridis Pharmaceuticals is working on an inhaled neutralizing antibody for COVID-19 dubbed AR-711, which was discovered using samples from patients who had recovered from COVID-19. The drug successfully cleared signs of SARS-CoV-2 virus from infected hamsters at a far lower dose compared with other experimental monoclonal antibodies, according to results published on preprint site bioRxiv.
- | Fountain Therapeutics
HQ Move Fuels Fountain’s AI Drug Discovery Machine
Fountain Therapeutics’ unique AI discovery platform prompted an invitation from Eli Lilly & Company to move Fountain headquarters to Lilly Gateway Labs. Company CEO Dr. John Dimos is making the most of it.
- | Fountain Therapeutics
SMA, NMOSD and Aging – From Few to Everyone
Moira speaks with Dr. Levi Garraway, the Chief Medical Officer of Genentech about FDA approvals for treatments in two very rare diseases – SMA – Spinal Muscular Atrophy, and NMOSD – Neuromyelitis Optica Spectrum Disorder.
- | Scynexis
Scynexis submits NDA for oral ibrexafungerp for vaginal yeast infection
Scynexis announced today that it has submitted a new drug application to the FDA for oral ibrexafungerp for the treatment of vulvovaginal candidiasis, the second most common cause of vaginitis.
- | Cardiff Oncology
Mark Erlander of Cardiff Oncology, Inc. Discusses KRAS Mutations in Cancer
Mark Erlander, Chief Executive Officer at Cardiff Oncology, Inc. talks KRAS mutations in cancer, and existing products like mCRC, mCRPc and AML, along with three clinical programs including Zytiga-Resistant Metastatic Castration Resistant Prostate cancer (mCRPC); KRAS mutated Metastatic Colorectal Cancer (mCRC) and Relapsed/Refractory Acute Myeloid Leukemia (AML). You can find out more here.
- | Cidara Therapeutics
Antiviral Conjugates – A Novel Treatment and Prevention Strategy for Viral Diseases Including COVID-19
Cidara Therapeutics has adopted key immuno-oncology principles and applied them to infectious disease, enabling the creation of a novel antiviral strategy – antiviral conjugates (AVCs). AVCs are long-acting, bispecific drugs that directly inhibit viral proliferation, whilst simultaneously
